Home › Funds › Vestal Point Capital, LP › ASND
Vestal Point Capital, LP position in ASND
ASCENDIS PHARMA A/S · Health Care
Vestal Point Capital, LP reported holding 375,000 shares of ASND (ASCENDIS PHARMA A/S) in its Q2 2026 13F filing — a position valued at US$100.0M, representing 2.34% of its reported portfolio and ranking #15 among its reported holdings. Vestal Point Capital, LP has disclosed ASND holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's ASND position evolved
Vestal Point Capital, LP first disclosed a stake in ASND in Q4 2023 at 625,000 shares (US$78.7M). The position peaked in Q3 2025 at 600,000 shares, worth US$119.3M. Across 11 filings, Vestal Point Capital, LP increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 375,000 shares valued at US$100.0M. Notable position changes include a 108% increase in Q4 2024 (shares rose 13% over the following quarter), a 200% increase in Q3 2025 (shares rose 7% over the following quarter), a 114% increase in Q1 2026 (shares rose 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 625.00K | $78.72M | New |
| Q1 2024 | 525.00K | $79.36M | Reduce |
| Q2 2024 | 750.00K | $102.28M | Add |
| Q3 2024 | 250.00K | $37.33M | Reduce |
| Q4 2024 | 520.00K | $71.59M | Add |
| Q1 2025 | 150.14K | $23.40M | Reduce |
| Q2 2025 | 200.00K | $34.52M | Add |
| Q3 2025 | 600.00K | $119.29M | Add |
| Q4 2025 | 175.00K | $37.32M | Reduce |
| Q1 2026 | 375.00K | $85.77M | Add |
| Q2 2026 | 375.00K | $100.02M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ASND and 13F data
ASND (ASCENDIS PHARMA A/S) is a Health Care company. 42 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ASND
- RA CAPITAL MANAGEMENT, L.P. 10.28M sh · $2.74B · Q2 2026
- T. Rowe Price Investment Management, Inc. 6.75M sh · $1.80B · Q2 2026
- Avoro Capital Advisors LLC 5.11M sh · $1.36B · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 4.80M sh · $1.28B · Q2 2026
- Jupiter Topco LLC 3.65M sh · $973.38M · Q2 2026
- Artisan Partners Limited Partnership 2.63M sh · $702.55M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.16M sh · $310.39M · Q2 2026
- Tri Locum Partners LP 258.74K sh · $69.01M · Q2 2026
- ORBIMED ADVISORS LLC 244.46K sh · $65.20M · Q2 2026
- PFM Health Sciences, LP 233.17K sh · $62.19M · Q2 2026
- Frazier Life Sciences Management, L.P. 225.16K sh · $60.05M · Q2 2026
- Spyglass Capital Management LLC 215.40K sh · $57.45M · Q2 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held ASND?
Vestal Point Capital, LP has disclosed ASND holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is Vestal Point Capital, LP's current position in ASND?
As of Q2 2026, Vestal Point Capital, LP holds 375.00K shares of ASND (ASCENDIS PHARMA A/S), valued at $100.02M, representing 2.34% of its reported portfolio and ranking #15.
Has Vestal Point Capital, LP been buying or selling ASND?
In the latest 13F filing (Q2 2026), Vestal Point Capital, LP held unchanged its position in ASND. The position peaked in Q3 2025 at 600.00K shares.
Which other funds hold ASND?
Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.